Literature DB >> 18500381

Indirect androgen doping by oestrogen blockade in sports.

D J Handelsman1.   

Abstract

Androgens can increase muscular mass and strength and remain the most frequently abused and widely available drugs used in sports doping. Banning the administration of natural or synthetic androgens has led to a variety of strategies to circumvent the ban of the most effective ergogenic agents for power sports. Among these, a variety of indirect androgen doping strategies aiming to produce a sustained rise in endogenous testosterone have been utilized. These include oestrogen blockade by drugs that act as oestrogen receptor antagonists (antioestrogen) or aromatase inhibitors. The physiological and pharmacological basis for the effects of oestrogen blockade in men, but not women, are reviewed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18500381      PMCID: PMC2439522          DOI: 10.1038/bjp.2008.150

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  126 in total

1.  Single-dose pharmacokinetics of clomiphene citrate in normal volunteers.

Authors:  T J Mikkelson; P D Kroboth; W J Cameron; L W Dittert; V Chungi; P J Manberg
Journal:  Fertil Steril       Date:  1986-09       Impact factor: 7.329

2.  Appraising the instantaneous secretory rates of luteinizing hormone and testosterone in response to selective mu opiate receptor blockade in late pubertal boys.

Authors:  N Mauras; A D Rogol; J D Veldhuis
Journal:  J Androl       Date:  1987 Jul-Aug

3.  Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.

Authors:  M Dowsett; D C Cunningham; R C Stein; S Evans; L Dehennin; A Hedley; R C Coombes
Journal:  Cancer Res       Date:  1989-03-01       Impact factor: 12.701

4.  Serum bioactive and immunoreactive follicle-stimulating hormone levels and the response to clomiphene in healthy young and elderly men.

Authors:  J S Tenover; K D Dahl; A J Hsueh; P Lim; A M Matsumoto; W J Bremner
Journal:  J Clin Endocrinol Metab       Date:  1987-06       Impact factor: 5.958

5.  Treatment of gynecomastia with tamoxifen: a double-blind crossover study.

Authors:  L N Parker; D R Gray; M K Lai; E R Levin
Journal:  Metabolism       Date:  1986-08       Impact factor: 8.694

6.  Participation of endogenous opiates in regulation of the hypothalamic-pituitary-testicular axis in normal men.

Authors:  G Delitala; M Giusti; G Mazzocchi; L Granziera; W Tarditi; G Giordano
Journal:  J Clin Endocrinol Metab       Date:  1983-12       Impact factor: 5.958

7.  Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.

Authors:  F Labrie; A Dupont; A Belanger; R Lachance
Journal:  J Urol       Date:  1987-10       Impact factor: 7.450

8.  Tamoxifen and testolactone in therapy of oligozoospermia: results of a randomized study.

Authors:  U Maier; G Hienert
Journal:  Eur Urol       Date:  1988       Impact factor: 20.096

9.  Evidence for a role of endogenous estrogen in the hypothalamic control of gonadotropin secretion in men.

Authors:  S J Winters; P Troen
Journal:  J Clin Endocrinol Metab       Date:  1985-11       Impact factor: 5.958

10.  Endogenous opiates modulate the pulsatile secretion of biologically active luteinizing hormone in man.

Authors:  J D Veldhuis; A D Rogol; M L Johnson
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

View more
  5 in total

1.  Drugs in sport.

Authors:  J C McGrath; D A Cowan
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

Review 2.  Drug abuse in athletes.

Authors:  Claudia L Reardon; Shane Creado
Journal:  Subst Abuse Rehabil       Date:  2014-08-14

3.  Impact of nonsteroidal aromatase inhibitors on steroid profile in a Chinese population.

Authors:  Yanyi Xing; Xin Liu; Mengmeng Yan; Tianqi Chen; Fei Lu; Bing Xu; Yan Gong; Fuhao Chu; Haimin Lei
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

4.  The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 5.  Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?

Authors:  Vito A Giagulli; Andrea Silvestrini; Carmine Bruno; Vincenzo Triggiani; Alvaro Mordente; Antonio Mancini
Journal:  Int J Endocrinol       Date:  2020-01-21       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.